DPI-4452 targets CAIX in tumors, offering noninvasive diagnostic potential for ccRCC with favorable tolerability. The agent is part of a theranostic pair wi ...

Benjamin, MD, discussed findings on the global oncology workforce and their implications of insufficient access to cancer ...

Biomarkers such as homologous recombination deficiency (HRD) and prostate-specific membrane antigen (PSMA) can sway treatment ...

A novel immune-based therapy shows 100% response rates in newly diagnosed multiple myeloma patients, highlighting its ...

HIF-2α inhibitors, like belzutifan, are emerging as promising second-line treatments for RCC, with ongoing trials showing ...

Beyond a cancer cell’s genetic blueprint, the expression levels of certain proteins on its surface is emerging as a collection of critical, actionable biomarkers. Instead of looking for a mutated gene ...

Avelumab demonstrated a 17% objective response rate in advanced penile cancer, with durable responses but limited survival benefits. Avelumab shows modest, durable responses in advanced penile cancer, ...

Pertuzumab-dpzb is the first interchangeable biosimilar to pertuzumab, enhancing treatment accessibility for HER2-positive ...

The FDA approves generic dasatinib tablets, enhancing access and affordability for treating chronic myeloid leukemia and ...

The FDA has accepted the new drug application (NDA) of the synthetic, targeted radiotherapeutic agent 177 Lu-edotreotide (ITM ...

The FDA has granted 501 (k) clearance to the EXENT® System, a fully automated device for assessing monoclonal gammopathies, ...

International collaboration is crucial for enhancing rural cancer care, with shared experiences and solutions from across the ...